GlassScriptPhysician profile
Maria Contreras
NPI 1285016246
$5,321.18
in general payments reported to CMS, 2019-2025
33 companies · $1,455 in 2025
The $1,455 reported for 2025 was more than what 92% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $971 · 2022: $1,319 · 2023: $1,251 · 2024: $325 · 2025: $1,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,031.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $459.08 | 2022-2025 | Strensiq, Ultomiris |
| Corcept Therapeutics | $294.82 | 2021-2025 | Korlym |
| Alnylam Pharmaceuticals INC. | $291.97 | 2023-2024 | Amvuttra, Onpattro |
| Amgen INC. | $286.48 | 2021-2025 | Evenity, Repatha |
| Abbvie INC. | $279.89 | 2022-2023 | |
| Medtronic, INC. | $270.23 | 2023-2025 | Interstim |
| Astrazeneca Pharmaceuticals LP | $269.51 | 2021-2024 | Airsupra, Farxiga |
| Teva Pharmaceuticals USA, INC. | $261.02 | 2021-2025 | Austedo Xr |
| Novo Nordisk INC | $237.16 | 2022-2023 | Wegovy |
| Ethicon INC. | $210.00 | 2021 | |
| Glaxosmithkline, LLC. | $205.65 | 2022-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.18 | 2022 | |
| Sk Life Science, INC. | $174.79 | 2021-2023 | Xcopri |
| Molnlycke Health Care US, LLC | $142.43 | 2021-2023 | Mepilex Border Post-Op, Mepilex Border Flex, Mepilex Border Sacrum |
| Lundbeck LLC | $124.99 | 2024 | Vyepti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $122.10 | 2021 | |
| Jazz Pharmaceuticals INC. | $122.06 | 2025 | |
| Gilead Sciences, INC. | $121.85 | 2025 | Epclusa |
| Eisai INC. | $121.16 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $120.86 | 2023 | Rexulti |
| Urovant Sciences INC | $110.13 | 2021 | |
| Axsome Therapeutics, INC. | $95.04 | 2025 | Auvelity |
| Shield Therapeutics INC | $93.01 | 2022 | |
| Janssen Scientific Affairs, LLC | $92.59 | 2025 | Tremfya |
| Neurocrine Biosciences, INC. | $89.23 | 2022-2025 | |
| Amarin Pharma, INC. | $89.21 | 2025 | Vascepa |
| Merck Sharp & Dohme LLC | $77.58 | 2021 | |
| Smith+Nephew, INC. | $70.05 | 2022 | |
| Pfizer INC. | $67.59 | 2025 | |
| Boston Scientific Corporation | $65.66 | 2022 | |
| Cmp Pharma, INC. | $63.09 | 2022 | |
| Acadia Pharmaceuticals INC | $61.82 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $40.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Contreras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.